Bicycle Therapeutics plc Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
Bicycle Therapeutics plc (BCYC) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $12.38 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-17.
Financial Statements › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2026-03-17
- Bicycle Therapeutics plc right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2023-12-31 was $0.00.
- Bicycle Therapeutics plc right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2023-09-30 was -$106.00K.
- Bicycle Therapeutics plc right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2023-06-30 was -$1.84M.
- Bicycle Therapeutics plc right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2023-03-31 was $5.85M, a 87.47% increase year-over-year.
- Bicycle Therapeutics plc right-of-use asset obtained in exchange for operating lease liability for fiscal 2025 was $12.38M.
- Bicycle Therapeutics plc right-of-use asset obtained in exchange for operating lease liability for fiscal 2023 was $3.90M, a 24.94% increase from fiscal 2022.
- Bicycle Therapeutics plc right-of-use asset obtained in exchange for operating lease liability for fiscal 2022 was $3.12M, a 77.47% decline from fiscal 2021.
- Bicycle Therapeutics plc right-of-use asset obtained in exchange for operating lease liability for fiscal 2021 was $13.85M.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2025-12-31 | $12.38M 10-K · filed 2026-03-17 | |||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | -$106.00K derived: sum of 2 quarters · filed 2026-03-17 | -$1.95M derived: sum of 3 quarters · filed 2026-03-17 | $3.90M 10-K · filed 2026-03-17 |
| 2023-09-30 | -$106.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | -$1.95M derived: sum of 2 quarters · filed 2024-10-31 | $3.90M 10-Q · filed 2024-10-31 | $3.90M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-06-30 | -$1.84M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $4.00M 10-Q · filed 2024-08-06 | $4.00M derived: sum of 3 quarters · filed 2025-02-25 | $4.00M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-03-31 | $5.85M 10-Q · filed 2024-05-02 | $5.85M derived: sum of 2 quarters · filed 2025-02-25 | $5.85M derived: sum of 3 quarters · filed 2025-02-25 | $5.85M derived: sum of 4 quarters · filed 2025-02-25 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $0.00 derived: sum of 2 quarters · filed 2025-02-25 | $0.00 derived: sum of 3 quarters · filed 2025-02-25 | $3.12M 10-K · filed 2025-02-25 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $0.00 derived: sum of 2 quarters · filed 2023-11-02 | $3.12M 10-Q · filed 2023-11-02 | |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $3.12M 10-Q · filed 2023-08-03 | ||
| 2022-03-31 | $3.12M 10-Q · filed 2023-05-04 | |||
| 2021-12-31 | $13.85M 10-K · filed 2024-02-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| ProMIS Neurosciences Inc. (PMN) | $0.102B |